Researchers monitor lasting effects of cancer drug in 20 patients
NCT ID NCT05017662
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study follows 20 people who previously received the drug 177Lu-satoreotide tetraxetan for neuroendocrine tumors. The goal is to watch for long-term side effects, including new cancers. No new treatment is given; it is purely a safety follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aarhus University Hospital
Aarhus, 8200, Denmark
-
Hôtel Dieu de Nantes
Nantes, 44093 Cedex 1, France
-
Medical University of Vienna
Vienna, 1090, Austria
-
Peter Maccallum Cancer Center
Melbourne, 3002, Australia
-
Ramsay Hollywood Private Hospital
Perth, 6009, Australia
-
Royal Free Hospital London
London, NW3 2QG, United Kingdom
-
University Hospital Basel
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.